Public Employees Retirement System of Ohio Lowers Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Public Employees Retirement System of Ohio lowered its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 58.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,138 shares of the company’s stock after selling 49,848 shares during the period. Public Employees Retirement System of Ohio owned 0.07% of Nurix Therapeutics worth $284,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in Nurix Therapeutics by 48.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock worth $4,469,000 after buying an additional 184,617 shares during the period. Kennedy Capital Management LLC lifted its holdings in Nurix Therapeutics by 192.7% during the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock worth $1,286,000 after buying an additional 107,719 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Nurix Therapeutics by 40.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company’s stock worth $1,446,000 after buying an additional 53,429 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Nurix Therapeutics by 14.7% during the 3rd quarter. ARK Investment Management LLC now owns 2,593,047 shares of the company’s stock valued at $20,381,000 after purchasing an additional 331,976 shares during the last quarter. Finally, Raymond James & Associates lifted its holdings in shares of Nurix Therapeutics by 6.0% during the 3rd quarter. Raymond James & Associates now owns 97,988 shares of the company’s stock valued at $770,000 after purchasing an additional 5,547 shares during the last quarter.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $10.02, for a total value of $68,256.24. Following the completion of the transaction, the chief financial officer now owns 68,333 shares in the company, valued at approximately $684,696.66. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 10,817 shares of company stock worth $100,256 in the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Nurix Therapeutics Stock Up 11.7 %

Shares of Nurix Therapeutics stock opened at $14.54 on Thursday. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $16.11. The business has a 50-day moving average price of $10.92 and a 200 day moving average price of $8.74. The firm has a market cap of $710.86 million, a PE ratio of -5.49 and a beta of 2.04.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Nurix Therapeutics had a negative net margin of 186.98% and a negative return on equity of 59.47%. The business had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $30.66 million. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -3.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on NRIX shares. Needham & Company LLC reiterated a “buy” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Friday, February 16th. Royal Bank of Canada decreased their price objective on Nurix Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Wells Fargo & Company decreased their price objective on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. Morgan Stanley increased their price objective on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, HC Wainwright decreased their price objective on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.